United-Guardian, Inc. (UG) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
United-Guardian, Inc. (UG) trades at $7.70 with AI Score 72/100 (Grade A). United-Guardian, Inc. manufactures and markets a diverse range of specialty products, including cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. Market cap: $35.4M, Sector: Consumer defensive.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026Analyst Coverage for UG: UG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UG against Consumer Defensive peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
UG: 1/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
United-Guardian, Inc. (UG) Consumer Business Overview
United-Guardian, Inc. (UG) is a manufacturer of specialty products including cosmetic ingredients like LUBRAJEL, pharmaceuticals such as RENACIDIN, medical lubricants, and industrial solutions. With a global presence and a focus on proprietary formulations, UG serves niche markets within the consumer defensive sector, supported by a 7.28% dividend yield.
What Is the Investment Thesis for UG?
United-Guardian, Inc. presents a compelling investment case centered on its niche market focus and consistent profitability. With a P/E ratio of 15.9 and a profit margin of 21.6%, the company demonstrates financial stability. The dividend yield of 7.28% offers an attractive income stream for investors. Growth catalysts include expanding the applications of its LUBRAJEL line and increasing market penetration for RENACIDIN and CLORPACTIN WCS-90. Key risks include reliance on a limited number of products and vulnerability to competition from larger players in the cosmetic ingredients and pharmaceutical sectors. The company's small market capitalization of $35.4M may limit liquidity.
Based on FMP financials and quantitative analysis
UG Key Highlights
- Market capitalization of $35.4M indicates a small-cap company with potential for growth.
- P/E ratio of 15.9 suggests the company may be undervalued compared to its earnings.
- Profit margin of 21.6% demonstrates strong profitability and efficient operations.
- Gross margin of 46.6% highlights the company's ability to maintain a healthy profit on its sales.
- Dividend yield of 7.28% provides a significant income stream for investors.
Who Are UG's Competitors?
UG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AXIL AXIL Brands, Inc. | $5.50 | -5.50% | $37.5M | 67 |
| KPTSF KP Tissue Inc. | $9.31 | +0.37% | $93.4M | 48 |
| NBBTF Natural Beauty Bio-Technology Limited | $0.06 | +0.00% | $122M | 57 |
| KITAF Kitanotatsujin Corporation | $0.97 | +0.00% | $135M | 49 |
| PURE PURE Bioscience, Inc. | $0.06 | +0.32% | $7.14M | 49 |
| ACU Acme United Corporation | $46.81 | -1.56% | $178M | 48 |
| DQWS DSwiss, Inc. | $0.03 | +0.00% | $6.41M | 54 |
| PTNM Pitanium Limited is a Hong Kong-based retailer specializing in beauty and personal care products under its proprietary brands, PITANIUM and BIG PI. The company | $10.39 | +0.00% | $208M | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UG's Key Strengths?
- Proprietary product formulations (e.g., LUBRAJEL)
- Established presence in niche markets
- Consistent profitability
- High dividend yield
What Are UG's Weaknesses?
- Small market capitalization
- Limited product diversification
- Reliance on a small number of employees
- Limited marketing resources
What Could Drive UG Stock Higher?
- Potential for new product approvals for pharmaceutical products.
- Expansion of the LUBRAJEL product line into new applications.
- Increased marketing efforts to drive sales growth in existing markets.
What Are the Key Risks for UG?
- Competition from larger companies with greater resources.
- Changes in regulatory requirements affecting the pharmaceutical and cosmetic industries.
- Economic downturns reducing demand for discretionary consumer products.
- Reliance on a small number of key employees.
What Are the Growth Opportunities for UG?
- Expansion of LUBRAJEL Product Line: United-Guardian can expand the LUBRAJEL product line into new cosmetic and personal care applications. The global market for cosmetic ingredients is estimated to reach $40 billion by 2027. By developing new LUBRAJEL formulations tailored to specific skin types and cosmetic products, United-Guardian can capture a larger share of this market. Timeline: Ongoing.
- Increased Market Penetration for RENACIDIN: United-Guardian can increase the market penetration of RENACIDIN, its prescription drug for urinary calcifications. The market for urological drugs is growing due to the aging population and increasing prevalence of urinary disorders. By expanding its marketing efforts and distribution network, United-Guardian can reach more patients and healthcare providers. Timeline: Ongoing.
- Development of New Pharmaceutical Products: United-Guardian can invest in research and development to develop new pharmaceutical products targeting unmet medical needs. The global pharmaceutical market is a multi-billion dollar industry, with significant opportunities for innovative treatments. By leveraging its expertise in drug formulation and regulatory affairs, United-Guardian can create new revenue streams. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: United-Guardian can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other companies in the cosmetic ingredients and pharmaceutical sectors can provide access to new technologies, distribution channels, and customer bases. Timeline: Ongoing.
- International Expansion: United-Guardian can expand its international presence by entering new markets and establishing local distribution partnerships. The global market for cosmetic ingredients and pharmaceuticals is growing rapidly in emerging economies. By adapting its products to local preferences and regulatory requirements, United-Guardian can tap into these new growth opportunities. Timeline: Ongoing.
What Opportunities Does UG Have?
- Expansion into new geographic markets
- Development of new product applications
- Strategic partnerships and acquisitions
- Increased demand for specialty chemicals and pharmaceuticals
What Threats Does UG Face?
- Competition from larger companies
- Changes in regulatory requirements
- Economic downturns
- Product liability claims
What Are UG's Competitive Advantages?
- Proprietary Formulations: United-Guardian's proprietary formulations, such as the LUBRAJEL line, provide a competitive advantage due to their unique properties and performance.
- Niche Market Focus: The company's focus on niche markets allows it to cater to specific customer needs and avoid direct competition with larger players.
- Established Customer Relationships: United-Guardian has established long-term relationships with its customers, providing a stable source of revenue.
- Regulatory Expertise: The company's expertise in regulatory affairs, particularly in the pharmaceutical sector, provides a barrier to entry for potential competitors.
What Does UG Do?
Founded in 1942 and headquartered in Hauppauge, New York, United-Guardian, Inc. has established itself as a manufacturer and marketer of a diverse range of specialty products. These include cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary industrial products. The company's cosmetic ingredient offerings feature the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, including variations like LUBRAJEL NATURAL, LUBRAJEL MARINE, LUBRASIL II SB, LUBRAJEL II XD, B-122, KLENSOFT, and ORCHID COMPLEX. These ingredients cater to various cosmetic applications, from pressed powders to skin creams. United-Guardian's medical lubricant products include LUBRAJEL RR, RC, MG, LC, FA, and FLUID, designed for applications such as urinary catheters and oral care. The pharmaceutical segment includes RENACIDIN, a prescription drug for urinary calcifications, and CLORPACTIN WCS-90, an antimicrobial product. Industrial products consist of DESELEX, a sequestering agent, and THOROCLENS, an industrial cleanser. United-Guardian markets its products through a network of marketing partners, distributors, and wholesalers, operating both in the United States and internationally.
What Products and Services Does UG Offer?
- Manufactures and markets cosmetic ingredients for various applications.
- Produces medical lubricants for use in medical procedures and devices.
- Develops and sells pharmaceutical products, including prescription drugs.
- Offers specialty industrial products, such as detergents and cleansers.
- Conducts research and development to create new and improved products.
- Markets products through marketing partners, distributors, and wholesalers, both domestically and internationally.
How Does UG Make Money?
- Develops and manufactures proprietary formulations for cosmetic, pharmaceutical, medical, and industrial applications.
- Markets and sells these products through a network of distributors, wholesalers, and marketing partners.
- Generates revenue from the sale of its products to end-users in various industries.
- Invests in research and development to create new products and improve existing ones.
What Industry Does UG Operate In?
United-Guardian operates within the consumer defensive sector, specifically in the household and personal products industry. This sector is generally stable, as demand for essential goods remains consistent regardless of economic conditions. The market for cosmetic ingredients and specialty pharmaceuticals is competitive, with larger companies often dominating. United-Guardian differentiates itself through its proprietary formulations and focus on niche applications. The company's success depends on its ability to innovate and maintain its competitive edge in these specialized markets.
Who Are UG's Key Customers?
- Cosmetic manufacturers who use United-Guardian's ingredients in their products.
- Healthcare providers who use United-Guardian's medical lubricants and pharmaceuticals.
- Industrial companies that use United-Guardian's specialty industrial products.
- Distributors and wholesalers who resell United-Guardian's products to end-users.
How United-Guardian, Inc. Is Valued
United-Guardian, Inc. carries a market capitalization of $35.4M, placing it in the micro-cap category. Relative to its peer group, UG's quantitative score of 72/100 is above the peer average of 54/100.
ROE 21%Key Financial Metrics
Return on equity for United-Guardian, Inc. stands at 21.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 18.6%, showing how much profit it generates from its asset base. UG trades at a trailing price-to-earnings ratio of 15.92, below the Consumer Defensive sector average of ~30x. Its free cash flow yield is 6.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
United-Guardian, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 15.29 places it in the safe zone, indicating low near-term bankruptcy risk.
UG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying activity has increased recently, suggesting confidence from management in the company's future prospects.
- Community sentiment has shifted positively, with discussions highlighting the company's strong product portfolio and market positioning.
- Recent announcements about new product launches have generated excitement among investors, indicating potential growth opportunities.
- The overall market perception of United-Guardian has improved, with analysts noting its resilience in a challenging economic environment.
Bear Case
- There are concerns regarding the company's revenue stability, as recent earnings reports showed fluctuations that have raised red flags among investors.
- Social sentiment has seen some bearish commentary, with traders expressing skepticism about the company's ability to sustain growth amid market competition.
- Insider selling activity has also been noted, which could indicate a lack of confidence from some executives regarding future performance.
- Market developments in the sector have introduced uncertainty, as competitors are gaining traction, potentially impacting United-Guardian's market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
UG Latest News
No recent news available for UG.
UG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UG.
Price Targets
Wall Street price target analysis for UG.
UG MoonshotScore
What does this score mean?
The MoonshotScore rates UG 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Donna Vigilante
CEO
Donna Vigilante serves as the CEO of United-Guardian, Inc. Her background includes extensive experience in managing small teams and overseeing the manufacturing and marketing of specialty chemical products. She has been with the company for a significant period, gaining a deep understanding of its operations, product lines, and customer base. Her leadership is focused on maintaining the company's profitability and expanding its market reach.
Track Record: Under Donna Vigilante's leadership, United-Guardian has maintained its consistent profitability and high dividend yield. She has overseen the development and launch of new LUBRAJEL formulations and has worked to expand the company's distribution network. Her strategic decisions have focused on maintaining the company's niche market focus and leveraging its proprietary formulations.
Common Questions About UG (Consumer Defensive)
What does the AI Score mean for UG?
UG holds an AI Score of 72/100 (Grade: A). This is an educational research signal, not a buy or sell recommendation. United-Guardian, Inc. manufactures and markets a diverse range of specialty products, including cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. The company …
What does United-Guardian, Inc. do?
United-Guardian, Inc. manufactures and markets a range of specialty products, including cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. Its cosmetic ingredients, such as the LUBRAJEL line, are used in various personal care products. The company's pharmaceutical products include RENACIDIN and CLORPACTIN WCS-90. Medical lubricants are used in healthcare settings, and industrial products include detergents and cleansers.
What do analysts say about UG stock?
Analyst coverage of United-Guardian, Inc. (UG) is limited due to its small market capitalization. However, key valuation metrics include a P/E ratio of 15.9 and a dividend yield of 7.28%. Growth considerations center on the company's ability to expand its product lines and increase market penetration. Investors should conduct their own due diligence and consider the company's financial performance and growth prospects.
What are the main risks for UG?
The main risks for United-Guardian, Inc. include competition from larger companies with greater resources, changes in regulatory requirements affecting the pharmaceutical and cosmetic industries, and economic downturns that could reduce demand for its products. The company's small size and limited product diversification also pose risks. Investors should carefully consider these risks before investing in UG.
What are the key factors to evaluate for UG?
United-Guardian, Inc. (UG) holds an AI score of 72/100 (high). P/E: 15.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does UG data refresh on this page?
UG's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven UG's recent stock price performance?
United-Guardian, Inc. (UG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary product formulations (e.g., LUBRAJEL). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UG overvalued or undervalued right now?
United-Guardian, Inc. (UG) trades at 15.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research UG before investing?
Before investing in United-Guardian, Inc. (UG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Limited analyst coverage may affect the accuracy of market sentiment analysis.